Editor Brian Harrod Provides Comprehensive up-to-date news coverage, with aggregated news from sources all over the world from the Roundup Newswires Network
The firms are already taking the lion’s share of earnings from the market, as this week’s results will show
Praised for preventing hundreds of thousands of deaths and allowing a return to more normal life, Covid vaccines will also substantially benefit some pharmaceutical companies.
Gladys Berejiklian says half of new cases were active in the community while infectious; Simon Birmingham admits Australia is ‘back of the queue’ for Pfizer vaccines; Atagi co-chair says AstraZeneca should only be used by under-40s in ‘pressing’ circumstances; Follow latest updates
Ahead of the daily health press conference in Victoria, premier Daniel Andrews has said he is “determined” to avoid another lockdown in the state, and part of that will be arguing in national cabinet on Friday for a reduction in the number of people able to return through hotel quarantine.
He repeated that it was better to lock out a small number of people than lock down whole cities or states, particularly while Victoria will not have a dedicated quarantine facility up and running in Mickleham until January.
Talk to your doctor, talk to your pharmacist. They’re the people to talk to, because whether it’s Atagi or others, there can be very broad statements made. Safety is always a concern – they are risk averse, they need to be. But everyone’s individual circumstances are different, and many people come to this question of ‘should I, shouldn’t I’ when, what vaccine with pre-existing conditions, with all sorts of other issues. So the best thing to do is not to be getting your epidemiological or your vaccination advice from politicians.
Talk to your GP, that’s what I would ask Victorians to do.
NSW police commissioner Mick Fuller is up now:
In the last 24 hours, 65 personnel infringement notices were issued. One of those of concern was a hairdresser in Auburn in the shopping area of Auburn.
In the last 24 hours, 65 personnel infringement notices were issued. One of those of concern was a hairdresser in Auburn in the shopping area of Auburn.
What police will be doing is matching our taskings to those areas and places of concern on the health website, but in particular today I want to send a very clear message that we will double our efforts in terms of visibility and compliance in south-western Sydney, in particular, around that Auburn, Bankstown area, in those shopping areas, the central business areas, and also back to the eastern suburbs as well. The message is quite clear – police continue to be visible in the community, on public transport. We are stopping and proposing many people and, again, it is just disappointing that infringements continue to be issued.
Amid bemusement from scientists at the deluge of often undeserved criticism, the Guardian pieces together the story behind the vaccine’s successes and failures
In January 2020, when most of the world slept soundly in ignorance of the pandemic coming its way, a group of scientists at Oxford University got to work on a vaccine to save the planet. They wanted it to be highly effective, cheap, and easy to use in even the poorest countries.
Prof Sarah Gilbert, Prof Andrew Pollard and others pulled it off. With speed crucial, they designed it and launched into trials before bringing in a business partner. The giant Anglo-Swedish pharmaceutical company AstraZeneca would manufacture it, license it around the world – and not make a profit until the pandemic was over.
Controversial vaccine to be given only by request later this year when Moderna and Pfizer will dominate
The federal government has announced it will shelve the controversial AstraZeneca vaccine by October, suggesting it will have enough supplies of other vaccines to meet “allocation horizons” for vaccinating the population by the end of the year.
The government released a revised planning document on Wednesday outlining how it intended to direct supplies over the rest of the year.
Drugmakers led by US firms Pfizer and Moderna stand to make tens of billions of dollars from their Covid-19 vaccines this year and next, given G7 governments’ pledge to vaccinate the entire world by the end of 2022, but sales are likely to drop sharply thereafter, according to analysts.
Acclaimed for allowing a return to more normal life, Covid vaccines will also substantially benefit some pharmaceutical companies. The global market for the vaccines is worth $70bn (£50bn) this year, says Karen Andersen of Morningstar.
The EU has failed in a legal attempt to secure an urgent 120m vaccine doses from AstraZeneca by the end of this month, while securing a judgment that sites in Oxford and Staffordshire should have been used in the past to make good on deliveries.
The court of first instance in Brussels ordered the Anglo-Swedish company to deliver just 10m more than it has already provided by the end of September, and make “best efforts”, including potentially the use of UK facilities, to provide the further 220m jabs to which it is contractually committed.
A 52-year-old woman from NSW who died after receiving the AstraZeneca vaccine is “likely” Australia’s second death from a rare and severe blood clotting syndrome linked to the Covid vaccine, Australia’s drugs regulator says.
The Therapeutic Goods Administration said on Thursday the woman had a severe form of the syndrome “with a blood clot in the brain known as a cerebral venous sinus thrombosis”.
Thailand has started its Covid vaccination campaign amid concerns over the supply of doses, which are mainly being produced locally by a royal-owned company that has no prior experience of making vaccines.
Thailand aims to vaccinate 70% of the population before the end of the year, and is relying primarily on AstraZeneca doses produced by Siam Bioscience, a company owned by King Maha Vajiralongkorn. The company is also due to supply vaccines to eight other countries in the region.
A team of German scientists believe that they have worked out why some people given the AstraZeneca and Johnson & Johnson vaccines against Covid-19 develop blood clots – and claim they can tell the manufacturers how to improve the vaccine to avoid it.
The key is in the adenovirus – the common cold virus that is used to deliver the spike protein of the coronavirus into the body, say Rolf Marschalek, a professor at Goethe university in Frankfurt, and colleagues. The mRNA vaccines developed by Pfizer/BioNTech and Moderna do not use this delivery system and there have been no blood clotting cases linked to them.
The European Commission has demanded an urgent court order requiring AstraZeneca to deliver millions more vaccines to the bloc or face a hefty fine, in a case that may reflect its anger more than its need for doses.
“AstraZeneca did not even try to respect the contract,” the EU’s lawyer, Rafaël Jafferali, told a court in Brussels on Wednesday, saying the EU wanted €10 per dose for each day of delay as compensation for the company’s alleged non-compliance.
The chief executive of AstraZeneca has defended the company against “armchair generals” and said its vaccine has a future.
Pascal Soriot disclosed the UK had priority access to the jab in a deal with Oxford University in return for investment and that it was only slightly less effective against the India variant than the strain identified in Kent.
Vaccine programmes across Africa and much of the developing world will suffer big delays after the world’s biggest producer said it would not be exporting the Oxford/AstraZeneca vaccine until the end of the year.
“We continue to scale up manufacturing and prioritise India … We also hope to start delivering to Covax and other countries by the end of this year,” Adar Poonawalla, chief executive of the Serum Institute of India (SII), said in a statement on Tuesday.
AstraZeneca has suffered a substantial shareholder rebellion over proposals to hand its chief executive, Pascal Soriot, bigger bonus awards for the second consecutive year.
Nearly 40% voted against the policy, which could hand him pay and perks of nearly £18m for 2021.
Three Covid medicines with the potential to “change the course” of the pandemic will be authorised for mass production and use in the EU by October under a European Commission plan.
Stella Kyriakides, the commissioner for health, said such a move would reduce hospitalisation and tackle the long-term impact of Covid, with one in 10 people reporting symptoms 12 weeks after infection.
AstraZeneca’s chief executive, Pascal Soriot, has mounted a robust defence of the drugmaker’s Covid-19 vaccine efforts, and said the business should be proud of what it has done for the world and is doing its “very best” to produce more, as the company faces legal action from the EU over delivery shortfalls, and shipments to poorer countries have also been delayed.
The company generated $275m (£197m) in revenues from the Covid vaccine it developed with Oxford University in the first three months of the year and shipped 48m doses to 120 countries through the global vaccine-sharing initiative Covax, 80% of which went to low and middle-income countries. In total, it has supplied more than 300m vaccine doses to more than 165 countries so far this year.
AstraZeneca said it would “strongly defend itself in court” and highlighted its supply of 50m Covid vaccine doses to European countries as Brussels launched legal action against the pharmaceutical company over delivery shortfalls.
The Anglo-Swedish firm said it regretted the decision by the European commission to start a legal case over alleged breaches of an advance purchase agreement.
EU capitals have been asked by the European commission to back legal action against AstraZeneca by the end of the week over an alleged breach of its contractual obligations to supply member states with its Covid vaccine.
At a meeting with commission officials on Wednesday, diplomats from some member states raised concerns about the wisdom of the move, warning against rushing into a decision that might further undermine confidence in the vaccine.
The global vaccine-sharing initiative Covax has so far delivered about one in five of the Oxford/AstraZeneca doses it estimated would arrive in countries by May, according to a Guardian analysis, starkly illustrating the cost of export bans, hoarding and supply shortages for a scheme that represents a key lifeline for many in the developing world.
The organisations that run Covax had predicted countries would receive fewer vaccines than expected after the Indian government restricted exports from its largest manufacturer in response to a catastrophic second wave there, but the figures reveal the shortfall to be severe, leaving many governments scrambling to secure doses elsewhere.
Marie Scully was alarmed and puzzled. “It didn’t make sense,” she said. The consultant haematologist at University College London hospital (UCLH) had seen patients with blood clots in the brain and low platelets before and, although it was unusual, she always knew why. But there was no reason for the condition of the young woman in her 30s she was treating in early March.
“Now when you have blood clots in the brain like that there’s always a cause, and it was difficult to pinpoint the cause,” said Prof Scully. “It didn’t fit our normal diagnostic boxes, let’s say. She was a young woman with cerebral venous sinus thrombosis, and she had a low platelet count.”